Publications by authors named "Paul W T J Leufkens"
Curr Clin Pharmacol
September 2021
Article Synopsis
- 2-iminobiotin (2-IB) is being tested as a neuroprotective agent to reduce brain cell damage after cerebral hypoxia-ischemia, and this study aimed to evaluate its safety and pharmacokinetics in healthy males.
- The randomized, double-blind, placebo-controlled study included healthy males who received varying doses of 2-IB, with results indicating that it was safe and well-tolerated up to doses of 6 mg/kg.
- While 2-IB showed a high clearance rate and linear pharmacokinetics, preliminary pharmacodynamics evaluations in a different model did not show significant effects relevant to its intended use for cerebral hypoxia-ischemia.
